[S02DA03, antipyrine, The metabolism of Bendamustine can be decreased when combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Bendamustine.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bendamustine.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Bendamustine.]
[L04AA27, fingolimod, Bendamustine may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bendamustine.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Bendamustine.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Bendamustine.]
[N06DA01, tacrine, The metabolism of Bendamustine can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The serum concentration of Bendamustine can be increased when it is combined with Tamoxifen.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Bendamustine.]
[B01AE07, dabigatran etexilate, The serum concentration of Bendamustine can be increased when it is combined with Dabigatran etexilate.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Tetracaine.]
[A04AD10, dronabinol, The metabolism of Bendamustine can be decreased when combined with Dronabinol.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Bendamustine.]
[R03DA07, theobromine, The metabolism of Bendamustine can be decreased when combined with Theobromine.]
[R03DA04, theophylline, The metabolism of Bendamustine can be decreased when combined with Theophylline.]
[P02CA02, thiabendazole, The metabolism of Bendamustine can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Bendamustine is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Bendamustine.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Bendamustine.]
[N05AF04, thiothixene, The metabolism of Bendamustine can be decreased when combined with Thiothixene.]
[B01AC05, ticlopidine, The metabolism of Bendamustine can be decreased when combined with Ticlopidine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Bendamustine.]
[N06AX05, trazodone, The serum concentration of Bendamustine can be decreased when it is combined with Trazodone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Bendamustine.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Bendamustine.]
[C03DB02, triamterene, The metabolism of Bendamustine can be decreased when combined with Triamterene.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Bendamustine.]
[N05AB06, trifluoperazine, The metabolism of Bendamustine can be decreased when combined with Trifluoperazine.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Bendamustine.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Bendamustine.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Bendamustine.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Belimumab.]
[L01EX04, vandetanib, The serum concentration of Bendamustine can be increased when it is combined with Vandetanib.]
[L02BX03, abiraterone, The serum concentration of Bendamustine can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The serum concentration of Bendamustine can be increased when it is combined with Linagliptin.]
[J05AP02, telaprevir, The serum concentration of Bendamustine can be increased when it is combined with Telaprevir.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Bendamustine.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Bendamustine.]
[B01AF01, rivaroxaban, The serum concentration of Bendamustine can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Bendamustine can be increased when it is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Bendamustine can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Bendamustine can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Bendamustine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Bendamustine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Bendamustine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Bendamustine.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bendamustine.]
[B01AA03, warfarin, The metabolism of Bendamustine can be decreased when combined with Warfarin.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Bendamustine.]
[L01EC01, vemurafenib, The serum concentration of Bendamustine can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Bendamustine is combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The serum concentration of Bendamustine can be increased when it is combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Bendamustine.]
[J01MA13, trovafloxacin, The metabolism of Bendamustine can be decreased when combined with Trovafloxacin.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bendamustine.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bendamustine.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Bendamustine is combined with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bendamustine.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Bendamustine.]
[L01EK01, axitinib, The metabolism of Bendamustine can be decreased when combined with Axitinib.]
[R07AX02, ivacaftor, The serum concentration of Bendamustine can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Bendamustine is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bendamustine.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Bendamustine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Bendamustine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Bendamustine.]
[G04BE10, avanafil, The serum concentration of Bendamustine can be increased when it is combined with Avanafil.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Bendamustine.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bendamustine.]
[A08AA11, lorcaserin, The metabolism of Bendamustine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Bendamustine can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Bendamustine can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Bendamustine can be increased when it is combined with Cobicistat.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Bosutinib is combined with Bendamustine.]
[L04AA31, teriflunomide, The serum concentration of Bendamustine can be decreased when it is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Bendamustine.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Bendamustine.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Bendamustine.]
[L01EX05, regorafenib, The serum concentration of Bendamustine can be increased when it is combined with Regorafenib.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Bendamustine is combined with Antilymphocyte immunoglobulin (horse).]
[J01MB04, pipemidic acid, The metabolism of Bendamustine can be decreased when combined with Pipemidic acid.]
[N04BD02, rasagiline, The metabolism of Bendamustine can be decreased when combined with Rasagiline.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Bendamustine.]
[L04AA29, tofacitinib, Bendamustine may increase the immunosuppressive activities of Tofacitinib.]
[N02CC03, zolmitriptan, The metabolism of Bendamustine can be decreased when combined with Zolmitriptan.]
[G04BE03, sildenafil, The serum concentration of Bendamustine can be increased when it is combined with Sildenafil.]
[L01EA05, ponatinib, The serum concentration of Bendamustine can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Bendamustine can be increased when it is combined with Apixaban.]
[C10AX12, lomitapide, The serum concentration of Bendamustine can be increased when it is combined with Lomitapide.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bendamustine.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Bendamustine is combined with Pomalidomide.]
[A10BK02, canagliflozin, The serum concentration of Bendamustine can be increased when it is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Bendamustine is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, The metabolism of Bendamustine can be decreased when combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The metabolism of Bendamustine can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Bendamustine can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Benzocaine.]
[L04AA18, everolimus, The serum concentration of Bendamustine can be increased when it is combined with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Bendamustine can be increased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Benzyl alcohol.]
[L01EB03, afatinib, The serum concentration of Bendamustine can be increased when it is combined with Afatinib.]
[J05AJ03, dolutegravir, The serum concentration of Bendamustine can be increased when it is combined with Dolutegravir.]
[C02KX05, riociguat, The serum concentration of Bendamustine can be increased when it is combined with Riociguat.]
[L03AA14, lipegfilgrastim, Bendamustine may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Bendamustine is combined with Ibrutinib.]
[J05AP05, simeprevir, The serum concentration of Bendamustine can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Bendamustine can be increased when it is combined with Sofosbuvir.]
[A10BK01, dapagliflozin, The metabolism of Bendamustine can be decreased when combined with Dapagliflozin.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Bendamustine.]
[L04AA32, apremilast, The metabolism of Bendamustine can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Bendamustine.]
[S01ED02, betaxolol, The metabolism of Bendamustine can be decreased when combined with Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Bendamustine.]
[L04AC11, siltuximab, The metabolism of Bendamustine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Bendamustine can be increased when it is combined with Ceritinib.]
[B01AC26, vorapaxar, The serum concentration of Bendamustine can be increased when it is combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The metabolism of Bendamustine can be decreased when combined with Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Bendamustine.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Bendamustine is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Bendamustine is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The serum concentration of Bendamustine can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Bendamustine can be increased when it is combined with Eliglustat.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Bendamustine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Bendamustine.]
[L01EX09, nintedanib, The serum concentration of Bendamustine can be increased when it is combined with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Blinatumomab.]
[J05AP09, dasabuvir, The serum concentration of Bendamustine can be increased when it is combined with Dasabuvir.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Bendamustine is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Bendamustine.]
[B01AF03, edoxaban, The serum concentration of Bendamustine can be increased when it is combined with Edoxaban.]
[N06AX11, mirtazapine, The metabolism of Bendamustine can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Bendamustine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Bendamustine can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Bendamustine can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Panobinostat is combined with Bendamustine.]
[J05AP07, daclatasvir, The serum concentration of Bendamustine can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Bendamustine can be decreased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Bendamustine.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Bendamustine.]
[J05AP06, asunaprevir, The serum concentration of Bendamustine can be increased when it is combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Bendamustine.]
[A04AD14, rolapitant, The serum concentration of Bendamustine can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Bendamustine can be increased when it is combined with Flibanserin.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Trabectedin is combined with Bendamustine.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Bendamustine.]
[J02AC05, isavuconazole, The serum concentration of Bendamustine can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Bendamustine can be decreased when it is combined with Osimertinib.]
[L01EE02, cobimetinib, The serum concentration of Bendamustine can be increased when it is combined with Cobimetinib.]
[B01AC27, selexipag, The serum concentration of Bendamustine can be increased when it is combined with Selexipag.]
[J05AP10, elbasvir, The serum concentration of Bendamustine can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Bendamustine can be increased when it is combined with Grazoprevir.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Ixekizumab.]
[L01XX52, venetoclax, The serum concentration of Bendamustine can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, The metabolism of Bendamustine can be decreased when combined with Bromazepam.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Bendamustine.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Bupivacaine.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Bendamustine.]
[L01XX27, arsenic trioxide, The serum concentration of Bendamustine can be increased when it is combined with Arsenic trioxide.]
[S01GX07, azelastine, The metabolism of Bendamustine can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Bendamustine can be decreased when combined with Rucaparib.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Brodalumab.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Bendamustine.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Bendamustine.]
[N06BC01, caffeine, The metabolism of Bendamustine can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bendamustine.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Bendamustine.]
[J05AE09, tipranavir, The serum concentration of Bendamustine can be decreased when it is combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Bendamustine can be increased when combined with Infliximab.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Sarilumab.]
[B01AF04, betrixaban, The serum concentration of Bendamustine can be increased when it is combined with Betrixaban.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Bendamustine.]
[L01XX59, enasidenib, The serum concentration of Bendamustine can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Bendamustine can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Bendamustine can be increased when it is combined with Inotuzumab ozogamicin.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Bendamustine.]
[L01EM02, copanlisib, The serum concentration of Bendamustine can be increased when it is combined with Copanlisib.]
[C07AB07, bisoprolol, The serum concentration of Bendamustine can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Bendamustine can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Bendamustine.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Bendamustine.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Bendamustine.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Bendamustine.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Bendamustine.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Capsaicin.]
[A10BK04, ertugliflozin, The serum concentration of Bendamustine can be increased when it is combined with Ertugliflozin.]
[L02BB05, apalutamide, The serum concentration of Bendamustine can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Bendamustine can be increased when it is combined with Carbamazepine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bendamustine.]
[C07AG02, carvedilol, The serum concentration of Bendamustine can be increased when it is combined with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Bendamustine can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Bendamustine can be increased when it is combined with Avatrombopag.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Bendamustine is combined with Baricitinib.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Bendamustine.]
[H01CC03, elagolix, The serum concentration of Bendamustine can be increased when it is combined with Elagolix.]
[N03AX17, stiripentol, The metabolism of Bendamustine can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Bendamustine can be increased when it is combined with Lusutrombopag.]
[L01EM04, duvelisib, The serum concentration of Bendamustine can be increased when it is combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Bendamustine can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Bendamustine can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Bendamustine can be increased when it is combined with Omadacycline.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Chloroprocaine.]
[R03DA02, oxtriphylline, The metabolism of Bendamustine can be decreased when combined with Oxtriphylline.]
[L01XK04, talazoparib, The serum concentration of Bendamustine can be increased when it is combined with Talazoparib.]
[R03BB08, revefenacin, The serum concentration of Bendamustine can be increased when it is combined with Revefenacin.]
[L01ED05, lorlatinib, The serum concentration of Bendamustine can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Bendamustine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Bendamustine.]
[L01EX12, larotrectinib, The serum concentration of Bendamustine can be increased when it is combined with Larotrectinib.]
[L01EX13, gilteritinib, The serum concentration of Bendamustine can be increased when it is combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Bendamustine can be increased when it is combined with Glasdegib.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Bendamustine.]
[B01AC23, cilostazol, The metabolism of Bendamustine can be decreased when combined with Cilostazol.]
[P02BX04, triclabendazole, The metabolism of Bendamustine can be decreased when combined with Triclabendazole.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Bendamustine is combined with Siponimod.]
[J01FA09, clarithromycin, The serum concentration of Bendamustine can be increased when it is combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Bendamustine can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Bendamustine can be increased when it is combined with Clobazam.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Bendamustine is combined with Cloprednol.]
[L04AB01, etanercept, The metabolism of Bendamustine can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Bendamustine is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Risankizumab.]
[L02BB06, darolutamide, The serum concentration of Bendamustine can be increased when it is combined with Darolutamide.]
[M03BX08, cyclobenzaprine, The metabolism of Bendamustine can be decreased when combined with Cyclobenzaprine.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Bendamustine is combined with Upadacitinib.]
[L01EJ02, fedratinib, The serum concentration of Bendamustine can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Bendamustine can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The metabolism of Bendamustine can be increased when combined with Pitolisant.]
[J01XX12, lefamulin, The serum concentration of Bendamustine can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The serum concentration of Bendamustine can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Bendamustine.]
[A10AE03, insulin, regular, pork, The metabolism of Bendamustine can be increased when combined with Insulin pork.]
[J01XX09, daptomycin, The serum concentration of Bendamustine can be increased when it is combined with Daptomycin.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Bendamustine is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Bendamustine.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Bendamustine.]
[N02CC08, lasmiditan, The serum concentration of Bendamustine can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Bendamustine is combined with Diroximel fumarate.]
[A16AX16, givosiran, The serum concentration of Bendamustine can be increased when it is combined with Givosiran.]
[N02CD04, ubrogepant, The serum concentration of Bendamustine can be increased when it is combined with Ubrogepant.]
[L01FX13, enfortumab vedotin, The serum concentration of Bendamustine can be increased when it is combined with Enfortumab vedotin.]
[N05CM21, lemborexant, The serum concentration of Bendamustine can be increased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The serum concentration of Bendamustine can be increased when it is combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bendamustine.]
[M01AX21, diacetylrhein, The metabolism of Bendamustine can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The serum concentration of Bendamustine can be increased when it is combined with Rimegepant.]
[S01AE06, gatifloxacin, The metabolism of Bendamustine can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The serum concentration of Bendamustine can be increased when it is combined with Osilodrostat.]
[N02CC07, frovatriptan, The metabolism of Bendamustine can be decreased when combined with Frovatriptan.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Bendamustine is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Bendamustine.]
[M01AH02, rofecoxib, The serum concentration of Bendamustine can be increased when it is combined with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Bendamustine.]
[C01BD07, dronedarone, The serum concentration of Bendamustine can be increased when it is combined with Dronedarone.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Bendamustine.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Bendamustine.]
[L01EH03, tucatinib, The serum concentration of Bendamustine can be increased when it is combined with Tucatinib.]
[L01EX17, capmatinib, The serum concentration of Bendamustine can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluprednidene.]
[L01EX19, ripretinib, The serum concentration of Bendamustine can be increased when it is combined with Ripretinib.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Bendamustine.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Bendamustine is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Bendamustine.]
[J05AX29, fostemsavir, The serum concentration of Bendamustine can be increased when it is combined with Fostemsavir.]
[L01FX15, belantamab mafodotin, The serum concentration of Bendamustine can be increased when it is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The serum concentration of Bendamustine can be decreased when it is combined with Satralizumab.]
[L01EX23, pralsetinib, The serum concentration of Bendamustine can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Bendamustine.]
[N05AA01, chlorpromazine, The metabolism of Bendamustine can be decreased when combined with Chlorpromazine.]
[M03BB03, chlorzoxazone, The metabolism of Bendamustine can be decreased when combined with Chlorzoxazone.]
[B06AC06, berotralstat, The serum concentration of Bendamustine can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Bendamustine can be increased when it is combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Bendamustine.]
[L02BX04, relugolix, The serum concentration of Bendamustine can be increased when it is combined with Relugolix.]
[L04AD03, voclosporin, The serum concentration of Bendamustine can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Bendamustine can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Bendamustine can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Bendamustine can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The metabolism of Bendamustine can be increased when combined with Trilaciclib.]
[N06BA10, fenethylline, The metabolism of Bendamustine can be decreased when combined with Fenethylline.]
[J01MB07, flumequine, The metabolism of Bendamustine can be decreased when combined with Flumequine.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Bendamustine.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Bendamustine.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Bendamustine is combined with Ponesimod.]
[L01EK03, tivozanib, The serum concentration of Bendamustine can be increased when it is combined with Tivozanib.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Bendamustine can be increased when it is combined with Peginterferon alfa-2b.]
[L01FX22, loncastuximab tesirine, The serum concentration of Bendamustine can be increased when it is combined with Loncastuximab tesirine.]
[A02BA01, cimetidine, The metabolism of Bendamustine can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The metabolism of Bendamustine can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The metabolism of Bendamustine can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Bendamustine can be increased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The serum concentration of Bendamustine can be increased when it is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Bendamustine.]
[N06AB04, citalopram, The metabolism of Bendamustine can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Bendamustine is combined with Pegcetacoplan.]
[H01AC07, somapacitan, The metabolism of Bendamustine can be increased when combined with Somapacitan.]
[L04AA48, belumosudil, The serum concentration of Bendamustine can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Bendamustine can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Anifrolumab.]
[H01AC09, lonapegsomatropin, The metabolism of Bendamustine can be increased when combined with Lonapegsomatropin.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Bendamustine can be increased when it is combined with Technetium Tc-99m sestamibi.]
[M01AG01, mefenamic acid, The metabolism of Bendamustine can be decreased when combined with Mefenamic acid.]
[N06AX25, St. John's wort extract, The serum concentration of Bendamustine can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Bendamustine can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Bendamustine can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Bendamustine is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The serum concentration of Bendamustine can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Bendamustine can be increased when it is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Bendamustine.]
[B06AX04, mitapivat, The serum concentration of Bendamustine can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Bendamustine can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Bendamustine can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, The metabolism of Bendamustine can be decreased when combined with Clomipramine.]
[S01EA04, clonidine, The metabolism of Bendamustine can be decreased when combined with Clonidine.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Bendamustine is combined with Deucravacitinib.]
[A04AA01, ondansetron, The metabolism of Bendamustine can be decreased when combined with Ondansetron.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Bendamustine is combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Bendamustine can be increased when it is combined with Futibatinib.]
[A10BK06, sotagliflozin, The serum concentration of Bendamustine can be increased when it is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Bendamustine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Bendamustine can be increased when combined with Bimekizumab.]
[M04AC01, colchicine, The serum concentration of Bendamustine can be increased when it is combined with Colchicine.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Bendamustine is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Bendamustine.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Bendamustine.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Bendamustine.]
[J02AC02, itraconazole, The serum concentration of Bendamustine can be increased when it is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Bendamustine.]
[S01AD03, acyclovir, The metabolism of Bendamustine can be decreased when combined with Acyclovir.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Bendamustine.]
[J02AC04, posaconazole, The serum concentration of Bendamustine can be increased when it is combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bendamustine.]
[N07BC04, lofexidine, The metabolism of Bendamustine can be decreased when combined with Lofexidine.]
[S01AE04, lomefloxacin, The metabolism of Bendamustine can be decreased when combined with Lomefloxacin.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Bendamustine is combined with Meprednisone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Bendamustine.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Bendamustine.]
[J05AF07, tenofovir disoproxil, The serum concentration of Bendamustine can be increased when it is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Bendamustine.]
[S01XA18, cyclosporine, Bendamustine may increase the immunosuppressive activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Bendamustine can be increased when combined with Armodafinil.]
[C03XA02, conivaptan, The serum concentration of Bendamustine can be increased when it is combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Bendamustine.]
[J05AF10, entecavir, The metabolism of Bendamustine can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The serum concentration of Bendamustine can be increased when it is combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Bendamustine can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Bendamustine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bendamustine.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bendamustine.]
[M01AX01, nabumetone, The metabolism of Bendamustine can be decreased when combined with Nabumetone.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Bendamustine.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Bendamustine.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bendamustine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Bendamustine.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bendamustine.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Dexamethasone is combined with Bendamustine.]
[A08AA04, dexfenfluramine, The metabolism of Bendamustine can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Bendamustine can be increased when combined with Adalimumab.]
[N06AB05, paroxetine, The metabolism of Bendamustine can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Bendamustine can be decreased when combined with Clopidogrel.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Bendamustine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Bendamustine can be decreased when combined with Diclofenac.]
[L01DC04, ixabepilone, The serum concentration of Bendamustine can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Bendamustine can be decreased when combined with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Bendamustine is combined with Pirarubicin.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Bendamustine is combined with Difluocortolone.]
[C01AA04, digitoxin, The serum concentration of Bendamustine can be increased when it is combined with Digitoxin.]
[C01AA05, digoxin, The serum concentration of Bendamustine can be increased when it is combined with Digoxin.]
[C02DB01, dihydralazine, The metabolism of Bendamustine can be decreased when combined with Dihydralazine.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bendamustine.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Bendamustine.]
[J05AE08, atazanavir, The metabolism of Bendamustine can be decreased when combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Pramocaine.]
[N06BC02, propentofylline, The metabolism of Bendamustine can be decreased when combined with Propentofylline.]
[C05CA03, diosmin, The serum concentration of Bendamustine can be increased when it is combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Bendamustine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Bendamustine.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bendamustine.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Bendamustine.]
[C01BA03, disopyramide, The metabolism of Bendamustine can be decreased when combined with Disopyramide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Natalizumab.]
[S02AA12, rifamycin SV, The serum concentration of Bendamustine can be increased when it is combined with Rifamycin.]
[N07XX02, riluzole, The metabolism of Bendamustine can be decreased when combined with Riluzole.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Bendamustine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Ropivacaine.]
[J01MB01, rosoxacin, The metabolism of Bendamustine can be decreased when combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Bendamustine.]
[C03XA01, tolvaptan, The serum concentration of Bendamustine can be increased when it is combined with Tolvaptan.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Bendamustine.]
[C02KX02, ambrisentan, The serum concentration of Bendamustine can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Bendamustine can be increased when it is combined with Ranolazine.]
[A03FA03, domperidone, The metabolism of Bendamustine can be decreased when combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Bendamustine can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The metabolism of Bendamustine can be decreased when combined with Doxepin.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Bendamustine.]
[C10AA01, simvastatin, The serum concentration of Bendamustine can be increased when it is combined with Simvastatin.]
[C07AB13, talinolol, The serum concentration of Bendamustine can be increased when it is combined with Talinolol.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Bendamustine.]
[J01MA05, temafloxacin, The metabolism of Bendamustine can be decreased when combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Bendamustine.]
[D01BA02, terbinafine, The metabolism of Bendamustine can be decreased when combined with Terbinafine.]
[L02BA02, toremifene, The serum concentration of Bendamustine can be increased when it is combined with Toremifene.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Bendamustine.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Bendamustine.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Bendamustine is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Bendamustine.]
[J01MA04, enoxacin, The serum concentration of Bendamustine can be increased when it is combined with Enoxacin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Bendamustine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Bendamustine.]
[N05CF02, zolpidem, The metabolism of Bendamustine can be decreased when combined with Zolpidem.]
[N03AX15, zonisamide, The serum concentration of Bendamustine can be increased when it is combined with Zonisamide.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Bendamustine.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Bendamustine.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Bendamustine.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Bendamustine.]
[S01AA17, erythromycin, The serum concentration of Bendamustine can be increased when it is combined with Erythromycin.]
[H05BX01, cinacalcet, The metabolism of Bendamustine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Bendamustine can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Bendamustine.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Bendamustine can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Bendamustine can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluticasone.]
[L02AA03, ethinyl estradiol, The metabolism of Bendamustine can be decreased when combined with Ethinylestradiol.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Bendamustine.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Bendamustine.]
[N06AB08, fluvoxamine, The serum concentration of Bendamustine can be increased when it is combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Bendamustine can be decreased when combined with Tocainide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Bendamustine.]
[C10AA03, pravastatin, The serum concentration of Bendamustine can be increased when it is combined with Pravastatin.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Bendamustine.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bendamustine.]
[A02BA03, famotidine, The metabolism of Bendamustine can be decreased when combined with Famotidine.]
[P02CA03, albendazole, The serum concentration of Bendamustine can be increased when it is combined with Albendazole.]
[N03AX26, fenfluramine, The metabolism of Bendamustine can be decreased when combined with Fenfluramine.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Bendamustine.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Bendamustine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Bendamustine.]
[C01BC04, flecainide, The metabolism of Bendamustine can be decreased when combined with Flecainide.]
[J02AC01, fluconazole, The serum concentration of Bendamustine can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Bendamustine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Bendamustine.]
[N07CA03, flunarizine, The metabolism of Bendamustine can be decreased when combined with Flunarizine.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Bendamustine.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Bendamustine can be decreased when combined with Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Bendamustine.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Bendamustine.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Bendamustine.]
[N06AB03, fluoxetine, The metabolism of Bendamustine can be decreased when combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bendamustine.]
[L02BB01, flutamide, The metabolism of Bendamustine can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Bendamustine.]
[J05AE10, darunavir, The serum concentration of Bendamustine can be increased when it is combined with Darunavir.]
[C10AB04, gemfibrozil, The metabolism of Bendamustine can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Bendamustine.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Bendamustine.]
[L01EH01, lapatinib, The serum concentration of Bendamustine can be increased when it is combined with Lapatinib.]
[N05CM18, dexmedetomidine, The metabolism of Bendamustine can be decreased when combined with Dexmedetomidine.]
[L01EX02, sorafenib, The serum concentration of Bendamustine can be increased when it is combined with Sorafenib.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Bendamustine.]
[N05AD01, haloperidol, The metabolism of Bendamustine can be decreased when combined with Haloperidol.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Bendamustine.]
[M04AA01, allopurinol, The risk or severity of rash, hypersensitivity reaction, Stevens-Johnson syndrome, and Cutaneous drug reaction can be increased when Allopurinol is combined with Bendamustine.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Bendamustine.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Bendamustine.]
[J05AG01, nevirapine, The metabolism of Bendamustine can be decreased when combined with Nevirapine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Bendamustine.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Bendamustine.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Bendamustine.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Bendamustine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Bendamustine.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Bendamustine.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Bendamustine.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Ifosfamide is combined with Bendamustine.]
[H01AC02, somatrem, The metabolism of Bendamustine can be increased when combined with Somatrem.]
[N06AA02, imipramine, The metabolism of Bendamustine can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendamustine.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Bendamustine is combined with Tixocortol.]
[M03BX02, tizanidine, The metabolism of Bendamustine can be decreased when combined with Tizanidine.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Bendamustine.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Bendamustine.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Bendamustine.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bendamustine.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Bendamustine.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Bendamustine can be increased when it is combined with Sitagliptin.]
[N05CH02, ramelteon, The metabolism of Bendamustine can be decreased when combined with Ramelteon.]
[L01XX35, anagrelide, The metabolism of Bendamustine can be decreased when combined with Anagrelide.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bendamustine.]
[J05AB13, penciclovir, The metabolism of Bendamustine can be decreased when combined with Penciclovir.]
[J04AC01, isoniazid, The metabolism of Bendamustine can be decreased when combined with Isoniazid.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Bendamustine.]
[H01AC01, somatropin, The metabolism of Bendamustine can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Bendamustine can be increased when combined with Tocilizumab.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Bendamustine.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Bendamustine.]
[J02AB02, ketoconazole, The serum concentration of Bendamustine can be increased when it is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The serum concentration of Bendamustine can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, The metabolism of Bendamustine can be decreased when combined with Olanzapine.]
[V03AC03, deferasirox, The serum concentration of Bendamustine can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Bendamustine can be increased when combined with Abatacept.]
[J01MB02, nalidixic acid, The metabolism of Bendamustine can be decreased when combined with Nalidixic acid.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Bendamustine.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Lidocaine.]
[N06BA13, armodafinil, The metabolism of Bendamustine can be increased when combined with Armodafinil.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Bendamustine.]
[A07DA03, loperamide, The serum concentration of Bendamustine can be increased when it is combined with Loperamide.]
[N05AH01, loxapine, The serum concentration of Bendamustine can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Bendamustine can be increased when it is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Bendamustine is combined with Pralatrexate.]
[L01EA03, nilotinib, The serum concentration of Bendamustine can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Bendamustine can be increased when it is combined with Mannitol.]
[N06AA21, maprotiline, The metabolism of Bendamustine can be decreased when combined with Maprotiline.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Bendamustine.]
[P01BC02, mefloquine, The serum concentration of Bendamustine can be increased when it is combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Bendamustine.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Bendamustine.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Bendamustine.]
[N05CH01, melatonin, The metabolism of Bendamustine can be decreased when combined with Melatonin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Bendamustine.]
[N03AB04, mephenytoin, The metabolism of Bendamustine can be decreased when combined with Mephenytoin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Mepivacaine.]
[N05AX13, paliperidone, The serum concentration of Bendamustine can be increased when it is combined with Paliperidone.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Bendamustine.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Bendamustine.]
[L04AX03, methotrexate, The excretion of Methotrexate can be decreased when combined with Bendamustine.]
[D05BA02, methoxsalen, The metabolism of Bendamustine can be decreased when combined with Methoxsalen.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Bendamustine.]
[V04CG05, methylene blue, The serum concentration of Bendamustine can be increased when it is combined with Methylene blue.]
[R03DA05, aminophylline, The metabolism of Bendamustine can be decreased when combined with Aminophylline.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Bendamustine.]
[A03FA01, metoclopramide, The metabolism of Bendamustine can be decreased when combined with Metoclopramide.]
[C01BB02, mexiletine, The metabolism of Bendamustine can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Bendamustine can be decreased when combined with Mianserin.]
[N02BB03, aminopyrine, The metabolism of Bendamustine can be decreased when combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Bendamustine.]
[G03XB01, mifepristone, The serum concentration of Bendamustine can be decreased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Bendamustine.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Bendamustine.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendamustine.]
[C01BD01, amiodarone, The serum concentration of Bendamustine can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Bendamustine can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The serum concentration of Bendamustine can be increased when it is combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Bendamustine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Bendamustine can be decreased when combined with Eltrombopag.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Bendamustine.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Pazopanib is combined with Bendamustine.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bendamustine.]
[G04CA04, silodosin, The serum concentration of Bendamustine can be increased when it is combined with Silodosin.]
[N03AB05, fosphenytoin, The metabolism of Bendamustine can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bendamustine.]
[J01CF06, nafcillin, The metabolism of Bendamustine can be increased when combined with Nafcillin.]
[L04AC03, anakinra, The metabolism of Bendamustine can be increased when combined with Anakinra.]
[M02AA12, naproxen, The metabolism of Bendamustine can be decreased when combined with Naproxen.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bendamustine.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Docetaxel is combined with Bendamustine.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Bendamustine.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Bendamustine.]
[P02DA01, niclosamide, The metabolism of Bendamustine can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The metabolism of Bendamustine can be decreased when combined with Nifedipine.]
[S01AE02, norfloxacin, The metabolism of Bendamustine can be decreased when combined with Norfloxacin.]
[A16AX07, sapropterin, The serum concentration of Bendamustine can be increased when it is combined with Sapropterin.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Bendamustine.]
[L03AB07, interferon beta-1a, The metabolism of Bendamustine can be decreased when combined with Interferon beta-1a.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Bendamustine.]
[L04AC04, rilonacept, The metabolism of Bendamustine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Bendamustine can be increased when combined with Omeprazole.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Bendamustine.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Bendamustine.]
[N05AH05, asenapine, The metabolism of Bendamustine can be decreased when combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Bendamustine.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Bendamustine.]
[J01MA03, pefloxacin, The metabolism of Bendamustine can be decreased when combined with Pefloxacin.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Bendamustine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bendamustine.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bendamustine.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Bendamustine.]
[C04AD03, pentoxifylline, The metabolism of Bendamustine can be decreased when combined with Pentoxifylline.]
[N05AB03, perphenazine, The metabolism of Bendamustine can be decreased when combined with Perphenazine.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bendamustine.]
[N02BE03, phenacetin, The metabolism of Bendamustine can be decreased when combined with Phenacetin.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Bendamustine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Bendamustine.]
[S01GA05, phenylephrine, The metabolism of Bendamustine can be increased when combined with Phenylephrine.]
[L04AB06, golimumab, The metabolism of Bendamustine can be increased when combined with Golimumab.]
[C08CX01, mibefradil, The serum concentration of Bendamustine can be increased when it is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Bendamustine can be decreased when combined with Pimozide.]
[J05AE01, saquinavir, The serum concentration of Bendamustine can be increased when it is combined with Saquinavir.]
[J01MA11, grepafloxacin, The metabolism of Bendamustine can be decreased when combined with Grepafloxacin.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Bendamustine.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Bendamustine.]
[A03AE01, alosetron, The metabolism of Bendamustine can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Bendamustine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Bendamustine.]
[J05AE03, ritonavir, The serum concentration of Bendamustine can be increased when it is combined with Ritonavir.]
[P02BA01, praziquantel, The metabolism of Bendamustine can be decreased when combined with Praziquantel.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Bendamustine.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Bendamustine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Bendamustine can be increased when combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Bendamustine can be increased when it is combined with Primidone.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Bendamustine.]
[N05AA03, promazine, The metabolism of Bendamustine can be decreased when combined with Promazine.]
[C01BC03, propafenone, The serum concentration of Bendamustine can be increased when it is combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Bendamustine can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The serum concentration of Bendamustine can be increased when it is combined with Romidepsin.]
[C07AA05, propranolol, The metabolism of Bendamustine can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Bendamustine.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Bendamustine.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Bendamustine.]
[C01BA01, quinidine, The serum concentration of Bendamustine can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Bendamustine can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Bendamustine can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The serum concentration of Bendamustine can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The serum concentration of Bendamustine can be increased when it is combined with Rifampicin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bendamustine.]
[N04BD01, selegiline, The metabolism of Bendamustine can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Bendamustine is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Bendamustine.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Bendamustine is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bendamustine.]
[N03AG01, valproic acid, The metabolism of Bendamustine can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Bendamustine is combined with Hydrocortisone butyrate.]
